INTRODUCTION
============

Lysophosphatidic acid (LPA) is a bioactive lipid that is concentrated in serum and is essential for a variety of cellular and developmental processes (reviewed in ([@b15-bt-23-1])). While LPA does play a structural role in cell membranes, extracellular LPA is a highly selective and specific activator of a class of G protein-coupled receptors (GPCRs) called LPA receptors (LPARs) (reviewed in ([@b99-bt-23-1])). There are currently six recognized LPARs, named LPA~1--6~, with clear homologs between human (*LPAR1-6*) and mouse (*Lpar1-6*) genes (reviewed in ([@b16-bt-23-1])). All six receptors are expressed throughout the body during development and adulthood in unique spatiotemporal patterns. These receptors are involved in a variety of necessary functions, including cell survival, proliferation, migration, differentiation, vascular regulation, and cytokine release (reviewed in ([@b99-bt-23-1])).

LPA can be produced in several ways through the activity of intracellular or extracellular enzymes. The two most prominent pathways involve the conversion of lysophosphatidyl choline (LPC) to LPA by autotaxin (ATX/*Enpp2*) ([@b89-bt-23-1]; [@b91-bt-23-1]) and conversion of phosphatidic acid to LPA by phospholipase A1 or A2 (PLA1/PLA2) ([@b23-bt-23-1]; [@b81-bt-23-1]). Intriguingly, ATX is highly expressed in blood, brain, kidney, the lymphatic system, and tissue surrounding injury ([@b3-bt-23-1]; [@b77-bt-23-1]; [@b42-bt-23-1]), suggesting important LPA-mediated mechanisms in these areas. Additionally, LPA is secreted by activated platelets and mature adipocytes ([@b21-bt-23-1]; [@b92-bt-23-1]; [@b75-bt-23-1]). Because of its important roles throughout the body, aberrant LPA signaling has also been implicated in several diseases. This review focuses on the agents that have been developed to modulate LPA signaling and tested in disease models.

LYSOPHOSPHATIDIC ACID RECEPTOR SIGNALING
========================================

Interest in LPA as a signaling molecule dates back to the late 1970s when effects on intracellular calcium release, platelet aggregation, and blood pressure were reported ([@b88-bt-23-1]; [@b26-bt-23-1]). While the involvement of G proteins was postulated ([@b60-bt-23-1]), the mechanism of LPA signaling was not elucidated until 1996 when the first LPA receptor was cloned ([@b33-bt-23-1]). Since the discovery of LPA~1~ (originally Vzg-1 or Edg-2), five other LPARs have been validated. LPA~2~ and LPA~3~ were elucidated through homology searches by comparing amino acid sequences to that of LPA~1~ ([@b1-bt-23-1]; [@b5-bt-23-1]). Through efforts aimed at finding ligands for orphan receptors, LPA~4~ and LPA~5~ were discovered ([@b64-bt-23-1]; [@b47-bt-23-1]; [@b50-bt-23-1]). Most recently, LPA~6~, a GPCR that is most closely related to LPA~4~, was added to the ranks of LPA receptors ([@b71-bt-23-1]; [@b95-bt-23-1]).

LPAR signaling occurs through a variety of intracellular cascades (reviewed in ([@b59-bt-23-1])) ([Fig. 1](#f1-bt-23-1){ref-type="fig"}). The binding of LPA or an LPA analog to its 7-transmembrane GPCR allows the G~α~ subunit to exchange used GDP for GTP. This results in G~α~ dissociating from G~β~ and G~γ~, allowing the G~α~ and G~βγ~ complexes to signal through downstream effectors. Several G~α~ subunits have been implicated in LPAR signaling, including G~α12/13~, G~αq/11~, G~αs~, and G~αi/O~. Downstream effectors include activation of several pathways. The G~α12/13~-mediated Rho/ROCK and Rho/SRF pathways have been implicated in cell motility, invasion, and cytoskeletal changes ([@b82-bt-23-1]; [@b45-bt-23-1]; [@b39-bt-23-1]). The G~αq/11~ pathway activates phospholipase C (PLC), which induces IP3, and subsequently initiates Ca~2+~ and diacyl glycerol signaling ([@b74-bt-23-1]). This cascade can result in vasodilation and a variety of transcriptional changes, including protein kinase C-induced cell growth, immune recruitment, and changes in learning and memory ([@b55-bt-23-1]; [@b80-bt-23-1]; [@b20-bt-23-1]; [@b73-bt-23-1]). Induction of the G~αs~ pathway leads to adenylyl cyclase (AC) activation and the production of cAMP, preventing cell migration ([@b41-bt-23-1]). Activation of G~αi/O~ is the most versatile, as downstream effectors include PLC, Ras/MAPK-induced morphological changes ([@b48-bt-23-1]), PI3K/Rac-mediated migration ([@b40-bt-23-1]), modulation of PI3K/Akt survival mechanisms ([@b43-bt-23-1]; [@b97-bt-23-1]), and inhibition of AC.

Each LPAR has multiple important regulatory functions throughout the body (reviewed in ([@b99-bt-23-1])). Many of these have been elucidated through the use of knockout animals, pharmacological LPAR agonists or antagonists, and gene association studies. The first discovered LPAR, LPA~1~, appears to be responsible for several developmental, physiological, and pathological processes. These include cell survival, proliferation, adhesion, migration, immune function, and myelination (reviewed in ([@b24-bt-23-1])). LPA~2~ signaling has also been implicated in cell survival, migration, immune function, and myelination (reviewed in ([@b37-bt-23-1])), often appearing to contribute to complementary LPA~1~ mechanisms ([@b18-bt-23-1]). LPA~3~, while expressed in many different tissues, is most heavily characterized as being involved in reproduction; it mediates fertility, embryo spacing, and embryo implantation ([@b96-bt-23-1]). LPA~4~ influences cell aggregation, cell adhesion, vascular development, and osteogenesis regulation (reviewed in ([@b59-bt-23-1])). Additionally, LPA~4~-mediated adhesion appears to counteract LPA~1~/LPA~2~-stimulated migration processes ([@b52-bt-23-1]). LPA~5~ also negatively regulates cell motility and is involved in chemokine release ([@b41-bt-23-1]; [@b56-bt-23-1]). Although LPA~6~ is the most recently discovered LPAR, several genome screening studies have been published linking mutations in LPA~6~ to genetic hair loss and autosomal recessive hypotrichosis, or "wooly hair" syndrome ([@b2-bt-23-1]; [@b71-bt-23-1]; [@b72-bt-23-1]). LPA~6~ is also under investigation for further functionality. The effects of LPAR signaling are outlined in [Figure 1](#f1-bt-23-1){ref-type="fig"}.

PHARMACOLOGICAL ADVANCES MODULATING LPA SIGNALING
=================================================

As LPAR signaling has been strongly implicated in many disease states, great interest has been expressed in developing specific LPAR inhibitors. Currently, no LPA or LPAR-targeting drugs have been FDA approved, though several are in development or undergoing clinical trials ([@b99-bt-23-1]) ([Table 1](#t1-bt-23-1){ref-type="table"}). Furthermore, the ability to develop safe and efficacious drugs targeting lysophospholipid signaling has already been proven; fingolimod (FTY720), an analog of sphingosine 1-phosphate (S1P) and inhibitor of S1P receptors, has been FDA-approved for the treatment of multiple sclerosis ([@b12-bt-23-1]; [@b16-bt-23-1]; [@b13-bt-23-1]).

LPA signaling has long been implicated in immune reactions (reviewed in ([@b54-bt-23-1])). To this end, several therapeutic advances have been made concerning autoimmune disorders. In fact, an LPA~1/3~ inhibitor, SAR100842, has completed phase II clinical trials to protect against systemic sclerosis ([@b76-bt-23-1]), an autoimmune disorder characterized by accumulated collagen in connective tissue, leading to scarring of the skin and vasculature ([@b49-bt-23-1]). LPA~1~ inhibitors are also of great interest in fibrosis, with BMS-986202 (previously AM152) having successfully completed phase I and BMS-986020 beginning phase II clinical trials for idiopathic pulmonary fibrosis (IPF) (2011, Amira Pharmaceuticals Announces Completion of Phase 1 Clnical Study for AM152, a Novel LPA1 Receptor Antagonist. In PR Newswire, [PRNewswire.com](PRNewswire.com). <http://www.prnewswire.com/news-releases/amira-pharmaceuticals-announces-completion-of-phase-1-clinical-study-for-am152-a-novel-lpa1-receptor-antagonist-121087874.html>, Access Date: 2014/09/15; [@b9-bt-23-1], [@b10-bt-23-1]). The LPA~1~ inhibitor AM966 and the LPA~1/3~ antagonist VPC12249 have also shown efficacy in murine IPF studies ([@b68-bt-23-1]; [@b86-bt-23-1]). Concurrently, an LPA~3~ agonist, oleoyl-methoxy phosphothionate (OMPT), enhanced IPF injury and reduced the therapeutic effects of VPC12249, suggesting that LPA~3~ signaling may also be relevant in fibrotic disease. The pan-LPAR antagonist HLZ-56 and LPA~1~ inhibitor AM095 attenuated kidney and dermal fibrosis in mouse models by preventing Smad2 phosphorylation, which reduced TGFβ signaling and subsequent CTGF release ([@b14-bt-23-1]; [@b85-bt-23-1]; [@b25-bt-23-1]), a mechanism that may be central to LPAR inhibitor effectiveness in other fibrotic disorders.

Much of the enthusiasm for LPAR therapies is directed at cancer, as LPAR signaling has been shown in numerous studies to promote motility and invasion of several cancer types, including breast, ovarian, colon, and brain tumors ([@b58-bt-23-1]; [@b31-bt-23-1]; [@b34-bt-23-1]; [@b32-bt-23-1]). *In vitro* studies utilizing the pan LPAR/ATX antagonist α-bromomethylene phosphonate LPA (BrP-LPA) and LPA~1/3~ antagonists Ki16425, Ki16198, and Debio 0719 have been shown to decrease tumor aggressiveness and increase radiosensitivity through varied mechanisms, including inhibited Rho/ROCK and MEK/ERK signaling, prevention of FAK/paxillin localization to focal adhesions, and reduced matrix metalloproteinase accumulation ([@b31-bt-23-1]; [@b100-bt-23-1]; [@b46-bt-23-1]; [@b57-bt-23-1]; [@b78-bt-23-1]; [@b53-bt-23-1]; [@b84-bt-23-1]). While many studies focus on the migratory effects of LPA~1~ signaling, use of the LPA~2~ inhibitor "compound 35" attenuated Erk phosphorylation and reduced proliferation of colorectal cancer cells ([@b6-bt-23-1]). LPA itself has been proposed as a screening molecule for ovarian cancer, as increased levels of LPA have been repeatedly observed in the blood of patients with malignant ovarian tumors and may have prognostic value in lung cancer patients as well ([@b79-bt-23-1]; [@b4-bt-23-1]; [@b62-bt-23-1]). Although no LPAR-targeting cancer drugs have reached clinical trial stages thus far, pharmaceutical inquiry is progressing rapidly and the initiation of cancerfocused clinical trials is projected to follow.

In addition to cancer and fibrosis, LPAR inhibitors have been utilized as potential therapeutics in other areas of study. For instance, Ki16425 and BrP-LPA have been shown to decrease the clinical score of murine arthritis ([@b63-bt-23-1]; [@b69-bt-23-1]). The development of an LPA-induced neonatal model of post-hemorrhagic hydrocephalus was also abrogated utilizing Ki16425 ([@b98-bt-23-1]). While LPA signaling is reported to be involved in wound-healing processes ([@b51-bt-23-1]), it may exacerbate severe trauma. In fact, anti-LPA antibodies that diminish LPAR binding and activation have shown some efficacy in modulating murine brain lesion severity and recovery ([@b28-bt-23-1]; [@b19-bt-23-1]), although the actual mechanism of these immunological agents remains to be determined. Additionally, Bristol- Myers Squibb has patented LPAR inhibitors for spinal cord injury and neuropathic pain indications ([@b65-bt-23-1]), since there is a substantial body of evidence implicating LPA~1~ and LPA~5~ signaling in the initiation and maintenance of neuropathic pain (reviewed in ([@b90-bt-23-1])).

The most common output for screening drug efficacy against an LPAR is determining the status of Ca^2+^ influx within the tested cell types. Generally, LPAR agonists will increase intracellular Ca^2+^ mobilization while LPAR antagonists will inhibit Ca^2+^ release. Using this method, several studies have been published on the synthesis and relative efficacy of potential therapeutics against LPA~1--3~, LPA~1--5~, and more recently LPA~1--6~ (reviewed in ([@b36-bt-23-1])). While this article only discusses pharmacological modulators with functional, disease-related readouts, a more comprehensive list of LPAR agonists and antagonists can be found in a previous review ([@b99-bt-23-1]).

COMPOUNDS TARGETING ATX INHIBITION
==================================

In addition to direct pharmacological modulation of LPARs, several research groups have targeted the upstream enzyme ATX for discovery of potential therapeutics ([Table 1](#t1-bt-23-1){ref-type="table"}). ATX inhibitors prevent the enzymatic conversion of LPC to LPA. As ATX expression can account for at least half of plasma LPA levels ([@b87-bt-23-1]; [@b93-bt-23-1]), these drugs ultimately attenuate LPA signaling. Although this pathway lies upstream of LPAR signaling, targeting ATX allows for structure-based drug design ([@b22-bt-23-1]; [@b44-bt-23-1]; [@b66-bt-23-1]), a process that is limited in LPAR drug discovery because of the lack of receptor crystal structures; work in progress should rectify this deficiency.

In particular, oncology researchers are interested in developing these agents. Several ATX inhibitors have been synthesized and tested in tumor migration, metastasis, survival, and radiosensitivity studies. These inhibitors include the small molecules ONO-8430506 ([@b7-bt-23-1]) and PF-8380 ([@b8-bt-23-1]; [@b83-bt-23-1]), lipid analogs 4PBPA ([@b30-bt-23-1]) and pan-ATX/LPAR antagonist BrP-LPA ([@b94-bt-23-1]; [@b78-bt-23-1]), and gintonin - a plant-derived LPA/ginseng glycolipoprotein complex that results in feedback inhibition of ATX through LPAR signaling ([@b35-bt-23-1]). These compounds ultimately reduced survival and invasive behaviors of *in vitro* cancer cells and tumor xenografts. As ATX and LPARs are often upregulated in cancer (reviewed in ([@b29-bt-23-1])), the success of these compounds in research may spur therapeutic development.

ATX antagonism is also being investigated as a solution to inflammatory disease. PF-8380 has been shown to drastically reduce plasma LPA concentrations during inflammation ([@b27-bt-23-1]), suggesting that targeting ATX may be useful to reduce chronic inflammation. As mentioned above, BrP-LPA has been utilized to ameliorate arthritis in mice ([@b63-bt-23-1]). Furthermore, GWJ-A-23 showed efficacy in attenuating allergen-induced asthmatic attacks and bleomycin-induced IPF ([@b67-bt-23-1]; [@b70-bt-23-1]). The effects of reduced LPA signaling stretch even further, as the potent ATX inhibitor S32826 has been utilized to decrease intraocular pressure in a rabbit model of glaucoma ([@b38-bt-23-1]).

CONCLUSION
==========

Over the past four decades, interest in the signaling lipid LPA has grown from understanding its synthesis to encompassing several key processes in development and disease. To this end, several compounds have been fine-tuned by researchers and pharmaceutical companies to inhibit LPARs and ATX in order to mitigate the destructive pathologies related to cancer, autoimmune diseases, and other afflictions. The LPA~1~-targeting inhibitors SAR100842, BMS-986202, and BMS-986020 have passed phase I or phase II clinical trials with the potential of advancing toward FDA approval. The increasing availability of chemical tool compounds will enhance our understanding of LPAR signaling mechanisms in disease towards the development of new disease-modifying therapeutics.
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![LPAR signaling and functional outcomes. LPAR signaling details are highlighted for each receptor, based on canonical GPCR pathways that have been validated. Dashed lines indicate preliminary data that require further confirmation. Activated downstream effectors are shown in green, inhibited effectors in red, and effectors that are differentially activated or inhibited in yellow. The cellular effects of activating each LPAR are listed beneath the Gα cascades, followed by ultimate phenotypical outcomes as highlighted in this review. Antagonism or functional knockout of each LPAR has been proven to inhibit these disorder phenotypes.](bt-23-1f1){#f1-bt-23-1}
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Summary of compounds that target LPA signaling. The name, target, structure and development stage for each LPA signaling antagonist discussed in the article are outlined, along with their therapeutic

  Drug               Target               Structure                                                       Phase               Indication                                    Reference
  ------------------ -------------------- --------------------------------------------------------------- ------------------- --------------------------------------------- ----------------------------------------------------------------------------------
  FTY720             S1P~1~, S1P~3--5~    ![](bt-23-1i1.jpg)                                              FDA approved        Multiple sclerosis                            ([@b12-bt-23-1]; [@b16-bt-23-1])
  BMS-986202/AM152   LPA~1~               See patent WO/2012/162592 A1 for more information               Phase I complete    Idiopathic pulmonary fibrosis                 ([@b9-bt-23-1]; [@b11-bt-23-1])
  BMS-986020         LPA~1~               See patent WO/2012/162592 A1 for more information               Phase II complete   Idiopathic pulmonary fibrosis                 ([@b10-bt-23-1]; [@b11-bt-23-1])
  VPC 12249          LPA~1~               ![](bt-23-1i2.jpg)                                              Preclinical         Idiopathic pulmonary fibrosis                 ([@b68-bt-23-1])
  AM966              LPA~1~               ![](bt-23-1i3.jpg)                                              Preclinical         Idiopathic pulmonary fibrosis                 ([@b86-bt-23-1])
  AM095              LPA~1~               ![](bt-23-1i4.jpg)                                              Preclinical         Dermal fibrosis, kidney fibrosis              ([@b14-bt-23-1]; [@b85-bt-23-1])
  BMS patent         LPA~1~               See patent WO/2013/070879 A1 for more information               Preclinical         Spinal injury, neuropathic pain               ([@b65-bt-23-1])
  SAR 100842         LPA~1~, LPA~3~       See patent WO/2012/162592 A1 for more information               Phase II complete   Systemic sclerosis                            ([@b11-bt-23-1]; [@b76-bt-23-1])
  Ki16425            LPA~1~, LPA~3~       ![](bt-23-1i5.jpg)                                              Preclinical         Cancer, rheumatoid arthritis, hydrocephalus   ([@b31-bt-23-1]; [@b53-bt-23-1]; [@b69-bt-23-1]; [@b84-bt-23-1]; [@b98-bt-23-1])
  Debio 0719         LPA~1~, LPA~3~       R-stereoisomer of Ki16425                                       Preclinical         Cancer                                        ([@b57-bt-23-1])
  Ki16198            LPA~1--3~            ![](bt-23-1i6.jpg)                                              Preclinical         Cancer                                        ([@b46-bt-23-1])
  Cmpd. 35           LPA~2~               ![](bt-23-1i7.jpg)                                              Preclinical         Cancer                                        ([@b6-bt-23-1])
  Anti-LPA           All LPAR signaling   Antibody                                                        Preclinical         Traumatic brain injury                        ([@b19-bt-23-1]; [@b28-bt-23-1])
  HLZ-56             All LPARs            Unavailable                                                     Preclinical         Kidney fibrosis                               ([@b25-bt-23-1])
  BrP-LPA            ATX, all LPARs       ![](bt-23-1i8.jpg)                                              Preclinical         Cancer, rheumatoid arthritis                  ([@b63-bt-23-1]; [@b78-bt-23-1]; [@b94-bt-23-1]; [@b100-bt-23-1])
  ONO-8430506        ATX                  ![](bt-23-1i9.jpg)Backbone only, see patent WO/2012/005227 A1   Preclinical         Cancer                                        ([@b7-bt-23-1]; [@b61-bt-23-1])
  PF-8380            ATX                  ![](bt-23-1i10.jpg)                                             Preclinical         Cancer, inflammation                          ([@b8-bt-23-1]; [@b27-bt-23-1]; [@b83-bt-23-1])
  4PBPA              ATX                  ![](bt-23-1i11.jpg)                                             Preclinical         Cancer                                        ([@b30-bt-23-1])
  Gintonin           ATX                  Glycolipoprotein, structure not available                       Preclinical         Cancer                                        ([@b35-bt-23-1])
  GWJ-A-23           ATX                  ![](bt-23-1i12.jpg)                                             Preclinical         Asthma, idiopathic pulmonary fibrosis         ([@b67-bt-23-1]; [@b70-bt-23-1])
  S32826             ATX                  ![](bt-23-1i13.jpg)                                             Preclinical         Glaucoma                                      ([@b38-bt-23-1])
